BSG and stroke disorder: A recently published study by Liu et al., evaluated the use of CD147 antagonist peptide-9 (AP9)-conjugated NPs directed at the plasma membrane glycoprotein receptor CD147, which has been found to contribute to secondary damage after stroke, by facilitating peripheral leukocyte infiltration and disrupting the BBB [169].